• Call Our Support
    +91-9958406102

  • Our Working Hours
    Mon - Sat: 9:30 am - 6 pm

Sun Pharma gets USFDA nod for generic Mesalamine Extended Release Capsules; Stock climbs 2.5%


Sun Pharmaceutical Industries Limited has introduced that it has obtained last approval from US FDA for its Abbreviated New Drug Software (ANDA) for generic Mesalamine Prolonged Launch Capsules, 500 mg.

The generic product approval relies on Pentasa Prolonged Launch Capsules, 500mg as a reference product.

As per March 2022 IQVIA Well being knowledge, Pentasa Prolonged Launch Capsules, 500mg had annualized gross sales of roughly US$ 213 million in USA.

On Friday at round 10:44 AM, Solar Prescription drugs was buying and selling at Rs871.10 apiece up by Rs20.95 or 2.46% from its earlier closing of Rs850.15 apiece on the BSE.



Source link

Get Access To Free Mt4 Indicators & Much More